Home/Indications/Inflammation

Inflammation

1 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Market Leaders

HARROW EYE

original drugs

Phase 3 Readouts Pro

5 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q2 2026

Ziltivekimab B

Novo Nordisk

Estimated · fresh NCT05021835

Q4 2026

Ziltivekimab

Novo Nordisk

Estimated · fresh NCT06200207

Q4 2026

KSI-101

Kodiak Sciences Inc

Estimated · aging NCT06996080

Unlock 2 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 4 mechanisms across 8 industry trials with a known mechanism of action.

See full pipeline →

Corticosteroid

4 trials 2 sponsors

Glucocorticoid receptor

2 trials 1 sponsor

Phospholipase A2

1 trials 1 sponsor

Beta-2 adrenergic receptor/Glucocorticoid receptor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

127 industry-sponsored trials across 70 sponsors

Showing 13 of 13 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novartis	Secukinumab s.c. injection	—	RECRUITING	2030-01-29	NCT04638647
Colgate Palmolive	Stannous Fluoride Toothpaste (SnF)	—	NOT YET RECRUITING	2026-12	NCT06966492
Ocumension Therapeutics (Shanghai) Co., Ltd	Dexycu	—	COMPLETED	2023-07-08	NCT06497699
SCF Pharma	—	—	COMPLETED	2023-04-05	NCT04897893
AstraZeneca	—	—	COMPLETED	2022-12-16	NCT03924635
Bactiguard AB	—	—	COMPLETED	2020-03-09	NCT02808000
Yuhan Corporation	high-dose rosuvastatin	—	COMPLETED	2019-07-23	NCT04056169
Laboratorios Sophia S.A de C.V.	PRO-155	—	COMPLETED	2018-09-14	NCT03521791
a2 Milk Company Ltd.	—	—	COMPLETED	2016-10-14	NCT03081845
Bausch & Lomb Incorporated	Loteprednol Etabonate	Glucocorticoid receptor	COMPLETED	2015-10-19	NCT01437982
Takeda	Tinoridine HCl	—	COMPLETED	2011-10	NCT01224756
AbbVie	Ketorolac 0.4%	—	COMPLETED	2009-08	NCT00791323
Bausch & Lomb Incorporated	Indomethacin ophthalmic solution	—	COMPLETED	2009-06	NCT00904904

Showing 42 of 42 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novo Nordisk	Ziltivekimab	—	RECRUITING	2026-10-01	NCT06200207
Kodiak Sciences Inc	KSI-101	—	RECRUITING	2027-02	NCT06996080
Kodiak Sciences Inc	KSI-101	—	RECRUITING	2027-04	NCT06990399
Novo Nordisk	Ziltivekimab B	—	ACTIVE NOT RECRUITING	2026-06-09	NCT05021835
RDC Clinical Pty Ltd	Maolactin	—	COMPLETED	2026-02-16	NCT06444763
RDC Clinical Pty Ltd	Maolactin	—	COMPLETED	2025-05-23	NCT06436781
Ocumension Therapeutics (Shanghai) Co., Ltd	Dexycu	—	COMPLETED	2023-11-24	NCT06429306
Oculis	OCS-01	—	COMPLETED	2023-06-22	NCT05147233
Formosa Pharmaceuticals, Inc.	APP13007, 0.05%	—	COMPLETED	2022-07-06	NCT04810962
Formosa Pharmaceuticals, Inc.	APP13007, 0.05%	—	COMPLETED	2022-03-17	NCT04739709
Sun Pharma Advanced Research Company Limited	SDN-037	—	COMPLETED	2020-03-05	NCT03426267
Sun Pharmaceutical Industries Limited	ISV-305	—	COMPLETED	2019-11-18	NCT03192150
Sun Pharmaceutical Industries Limited	ISV-305	—	COMPLETED	2019-04-17	NCT03192137
Fidia Farmaceutici s.p.a.	Diclofenac Sodium 140 mg medicated plaster	—	COMPLETED	2018-10-27	NCT04976088
Kala Pharmaceuticals, Inc.	KPI-121 1% Ophthalmic Suspension dosed BID	—	COMPLETED	2017-03	NCT02793817
EMS	Nimesulide + Pantoprazole	—	COMPLETED	2016-10-28	NCT01670552
Ocular Therapeutix, Inc.	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2016-05	NCT02736175
Xigen SA	XG-102	—	COMPLETED	2016-01	NCT02508337
Xigen SA	XG-102	—	COMPLETED	2015-12	NCT02235272
Bausch & Lomb Incorporated	Loteprednol Etabonate Gel (BID)	—	COMPLETED	2015-03	NCT02208297
Ocular Therapeutix, Inc.	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2015-01	NCT02089113
Kala Pharmaceuticals, Inc.	KPI-121 0.25%	—	COMPLETED	2014-12	NCT02163824
Ocular Therapeutix, Inc.	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2014-12	NCT02034019
Actavis Inc.	clindamycin phosphate vaginal cream 2%	—	COMPLETED	2014-10	NCT02210689
ICON Bioscience Inc	IBI-10090	—	COMPLETED	2014-10	NCT02006888
Bausch & Lomb Incorporated	Loteprednol Etabonate Gel (BID)	—	COMPLETED	2014-05	NCT01996839
Alloksys Life Sciences B.V.	bIAP bolus and 8h infusion	—	COMPLETED	2013-12	NCT01144611
Bausch & Lomb Incorporated	Mapracorat	—	COMPLETED	2013-09	NCT01591655
Melinta Therapeutics, Inc.	Single-Dose IV Oritavancin Diphosphate	—	COMPLETED	2013-06	NCT01252732
Bausch & Lomb Incorporated	Mapracorat	—	COMPLETED	2013-06	NCT01591161
Melinta Therapeutics, Inc.	Single-Dose IV Oritavancin Diphosphate	—	COMPLETED	2012-10	NCT01252719
Alcon Research	Difluprednate ophthalmic emulsion, 0.05%	—	COMPLETED	2012-04	NCT01124045
Molnlycke Health Care AB	—	—	COMPLETED	2011-09	NCT01214811
Bausch & Lomb Incorporated	Bromfenac Ophthalmic Solution	—	COMPLETED	2011-07	NCT01367249
Azidus Brasil	Ster	—	COMPLETED	2011-02	NCT01227876
Bausch & Lomb Incorporated	Loteprednol etabonate	Glucocorticoid receptor	COMPLETED	2010-09	NCT01060072
Bausch & Lomb Incorporated	Vehicle of Loteprednol Etabonate	—	COMPLETED	2010-06	NCT01010633
Bausch & Lomb Incorporated	Bromfenac Ophthalmic Solution	—	COMPLETED	2009-09	NCT00853970
Sirion Therapeutics, Inc.	Difluprednate	Phospholipase A2	COMPLETED	2008-03	NCT00616993
Oculis	Dexamethasone Ophthalmic Suspension	—	TERMINATED	2024-05-02	NCT06128369
Bausch & Lomb Incorporated	Mapracorat	—	TERMINATED	2011-09	NCT01298752
Ache Laboratorios Farmaceuticos S.A.	diphenhydramine + dropropizine + pseudoephedrine	—	WITHDRAWN	2012-04	NCT01177852

Showing 41 of 41 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Abcentra	Orticumab	—	RECRUITING	2027-02-08	NCT06927739
Biogen	Felzartamab	—	RECRUITING	2028-02-10	NCT07219043
HoHo Biotech	—	—	RECRUITING	2024-12-29	NCT06401785
Novartis	MAS825	—	ACTIVE NOT RECRUITING	2025-10-14	NCT04641442
Reveal Pharmaceuticals Inc.	RVP-001	—	COMPLETED	2025-12-19	NCT06322342
VivaVision Biotech, Inc	VVN461 Ophthalmic Solution 1.0%	—	COMPLETED	2024-05-15	NCT06164743
Xalud Therapeutics, Inc.	XT-150	—	COMPLETED	2023-09-20	NCT05196919
Abcentra	Orticumab	—	COMPLETED	2022-11-11	NCT04776629
Novo Nordisk	Ziltivekimab	—	COMPLETED	2021-08-03	NCT04626505
Surface Ophthalmics, Inc.	SURF-201	—	COMPLETED	2020-11-03	NCT04324359
Tarsier Pharma	TRS01 eye drops	—	COMPLETED	2020-07-17	NCT04222725
Novo Nordisk	Ziltivekimab	—	COMPLETED	2020-06-26	NCT03926117
Formosa Pharmaceuticals, Inc.	APP13007, 0.05%	—	COMPLETED	2020-04-07	NCT04089735
Oculis	OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL	—	COMPLETED	2020-01-31	NCT04130802
iDrop, Inc.	Dexamethasone	Corticosteroid [EPC]	COMPLETED	2019-02-28	NCT03687931
Mati Therapeutics Inc.	—	—	COMPLETED	2018-12-17	NCT03496467
Natural Origins	—	—	COMPLETED	2018-10-08	NCT04150211
Church & Dwight Company, Inc.	Dentifrices	—	COMPLETED	2018-08-24	NCT03988374
Eyegate Pharmaceuticals, Inc.	—	—	COMPLETED	2017-11-07	NCT03180255
Liminal BioSciences Ltd.	PBI-4050	—	COMPLETED	2017-09-26	NCT02739217
A.T. Resolve SARL	RX-10045	—	COMPLETED	2015-09	NCT02329743
Novo Nordisk	NNC0114-0006	—	COMPLETED	2014-12	NCT01751152
Biogen	Omaveloxolone Ophthalmic Suspension 1.0%	—	COMPLETED	2014-09-30	NCT02065375
Johnson & Johnson Vision Care, Inc.	—	—	COMPLETED	2014-02	NCT01437319
Ocular Therapeutix, Inc.	OTX-DP (Dexamethasone punctum plug)	—	COMPLETED	2013-08	NCT01666210
Novo Nordisk	NNC0114-0006	—	COMPLETED	2013-08	NCT01647451
Johnson & Johnson	NNC 0142-0000-0002	—	COMPLETED	2013-05	NCT01203631
ICON Bioscience Inc	IBI-10090	—	COMPLETED	2013-03	NCT01606735
Novo Nordisk	NNC 0151-0000-0000	—	COMPLETED	2013-02	NCT01223911
Johnson & Johnson	NNC0142-0002	—	COMPLETED	2012-04	NCT01181050
Novo Nordisk	NNC109-0012	—	COMPLETED	2012-01	NCT01282255
Bausch & Lomb Incorporated	BOL-303242-X	—	COMPLETED	2010-03	NCT00905450
Organon and Co	mometasone furoate/formoterol 100/10 mcg	—	COMPLETED	2009-06	NCT00635882
PhaseBio Pharmaceuticals Inc.	Pemziviptadil (PB1046)	—	TERMINATED	2020-12-02	NCT04433546
Athera Biotechnologies AB	PC-mAb	—	TERMINATED	2018-03-19	NCT03320265
Novo Nordisk	NNC0109-0012	—	TERMINATED	2014-11-10	NCT01636843
Novo Nordisk	NNC0109-0012	—	TERMINATED	2014-11	NCT01636817
Novo Nordisk	catridecacog	—	TERMINATED	2013-07	NCT01706159
Robert W. Alexander, MD, FICS	IV Sterile Normal Saline	—	WITHDRAWN	2022-12	NCT02961114
Novo Nordisk	NNC0109-0012	—	WITHDRAWN	2015-09	NCT02097264
Izun Pharma Ltd	Transmucosal Herbal Periodontal Patch (THPP)	—	SUSPENDED	—	NCT00731432

Showing 31 of 31 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Redx Pharma Ltd	RXC007	—	COMPLETED	2023-03-08	NCT04931147
OrchestratePharma GmbH	Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)	—	COMPLETED	2022-10-16	NCT05461456
Liminal BioSciences Ltd.	PBI-4050/ Placebo	—	COMPLETED	2021-10-05	NCT04695041
Bristol-Myers Squibb	BMS-986235	—	COMPLETED	2021-07-02	NCT03335553
Kinevant Sciences GmbH	KIN-1901	—	COMPLETED	2020-04-07	NCT04205851
Novartis	Generic Loteprednol Etabonate	—	COMPLETED	2019-09-07	NCT03531697
Bayer	BAY1834845	—	COMPLETED	2018-01-22	NCT03244462
Pfizer	[11C]PF-06809247	—	COMPLETED	2017-03-10	NCT03100136
Novo Nordisk	NNC0215-0384	—	COMPLETED	2014-10	NCT01955603
Innate Pharma	NNC 0141-0000-0100	—	COMPLETED	2014-03	NCT01370902
Novo Nordisk	NNC0114-0006	—	COMPLETED	2013-10	NCT01565408
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2013-10	NCT01944228
Novo Nordisk	NNC0215-0384	—	COMPLETED	2013-06-17	NCT01611688
TME Pharma AG	NOX-H94	—	COMPLETED	2012-03	NCT01372137
Novo Nordisk	NNC0114-0000-0005	—	COMPLETED	2012-02	NCT01208506
Johnson & Johnson	NNC0142-0002	—	COMPLETED	2011-12	NCT00927927
Argos Therapeutics	AGS-009	—	COMPLETED	2011-12	NCT00960362
Xigen SA	XG-102	—	COMPLETED	2011-11	NCT01570205
Laboratorios Sophia S.A de C.V.	Bromfenac	—	COMPLETED	2011-10	NCT01535443
GSK	Cantharidin solution	—	COMPLETED	2011-01-14	NCT01762787
Novo Nordisk	anti-IL-20	—	COMPLETED	2010-12	NCT01038674
X-pert Med GmbH	Ibuprofen, Hydrocortisone	—	COMPLETED	2010-06	NCT01055249
Novo Nordisk	anti-IL-20	—	COMPLETED	2010-01	NCT00818064
GSK	Azithromycin	—	COMPLETED	2009-11-27	NCT01026064
Novo Nordisk	NNC 0151-0000-0000	—	COMPLETED	2009-10	NCT02151409
Merck	fluticasone propionate	Beta-2 adrenergic receptor/Glucocorticoid receptor	COMPLETED	2009-09	NCT00869596
Lallemand SAS	Lactobacillus farciminis	—	COMPLETED	2009-04	NCT00852865
Synspira, Inc.	Inhaled SNSP113	—	TERMINATED	2017-12-18	NCT03309358
Novo Nordisk	NNC0114-0006	—	TERMINATED	2014-02	NCT01689025
Novo Nordisk	anti-IL-20	—	TERMINATED	2011-01	NCT01261767
Novo Nordisk	NNC 0151-0000-0000	—	WITHDRAWN	2009-11	NCT01018238

Novel Drugs by Company (New molecular entities)

HARROW EYE 1 drug

NEVANAC

NEPAFENAC

NDA 2005

Reformulations (11 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.